Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
Round 1
Reviewer 1 Report
It is a well written and well organised review on immunotherapy in NSCLC. I would recommend adding more tables displaying also trials on monotherapy with PD-1/PD-L1 inhibitors and combo trials with PD-1/PD-L1 + CTLA 4 inhibitors. Structurally the same tables as table 1 in the article.
Author Response
Thank you so much for your favorable comment to our review paper.
In this review, we focused on pivotal clinical trials and molecular oncology regarding PD-1/PD-L1 inhibitor in NSCLC. The pivotal phase III trials, which effect on the therapeutic strategy of 1st line, were summarized in Table1, including PD1/PD-L1 monotherapy (KEYNOTE-024, KEYNOTE-042 and IMpower110) and addition of anti-CTLA4 (CheckMate 227, CheckMate 9LA and POSEIDON). We consider that these results are enough to indicate as pivotal clinical trials.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
This review article that submitted by Tanaka and Morise collected the use of immune checkpoint inhibitor (ICI) in recent clinical trials and summarized which gene mutations could influence the ICI efficacy. The overall manuscript is well written and well organizing. It seems to reach the criterion for publish.
Author Response
Thank you so much for your favorable comment to our review paper.
We are honored to receive the words from you.
